Want to see IN:STAR full AI Analyst Report?
Top Page
Strides Pharma Science Ltd
(STAR)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹1,047.00
▲(6.50% Upside)
Action:Downgraded
Date:08/21/26
The score is primarily supported by improving fundamentals (profitability rebound, stronger margins, and better leverage), but is held back by weak free-cash-flow conversion and a bearish technical backdrop (below key moving averages with negative MACD). Valuation is reasonable and provides some support, though the low dividend yield limits downside cushion.
Positive Factors
Profitability Turnaround
The shift from losses in 2022–2024 to solid profitability in 2025–2026 indicates improved operating execution. Sustained revenue growth and stronger margins can enhance earnings power if the company maintains product and market discipline.
Negative Factors
Weak Free-Cash-Flow Conversion
Weak conversion of accounting earnings into cash limits the funds available for debt reduction, research investment, and shareholder returns. Continued volatility, including prior negative free cash flow, raises questions about earnings quality and cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Turnaround
The shift from losses in 2022–2024 to solid profitability in 2025–2026 indicates improved operating execution. Sustained revenue growth and stronger margins can enhance earnings power if the company maintains product and market discipline.
Read all positive factors
Strides Pharma Science Ltd (STAR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹94.44B
Dividend Yield0.49%
Average Volume (3M)26.22K
Price to Earnings (P/E)15.4
Beta (1Y)0.90
Revenue Growth7.28%
EPS Growth68.82%
CountryIN
Employees3,535
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)60.35
Shares Outstanding92,172,714
10 Day Avg. Volume50,988
30 Day Avg. Volume26,222
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.78
Price to Sales (P/S)1.78
P/FCF Ratio71.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)68.3
Revenue Forecast (FY)₹56.72B
Strides Pharma Science Ltd Business Overview & Revenue Model
Company Description
Strides Pharma Science Limited is a pharmaceutical company that focuses on the development, production, and worldwide commercialization of medicinal products. Its extensive global footprint spans Africa, Australia, North America, Europe, Asia, Ind...
How the Company Makes Money
Strides primarily makes money by selling finished pharmaceutical formulations (mainly generic medicines) to customers in domestic and international markets. Key revenue streams typically include: (1) Sales of generic formulations: revenue generate...
Strides Pharma Science Ltd Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
68
Positive
Cash Flow
55
Neutral
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 48.59B | 44.75B | 38.28B | 36.68B | 30.59B |
| Gross Profit | 17.69B | 11.83B | 8.51B | 8.05B | 4.11B |
| EBITDA | 10.50B | 9.27B | 3.78B | 2.17B | -2.45B |
| Net Income | 5.56B | 4.05B | -1.20B | -2.21B | -4.60B |
Balance Sheet | |||||
| Total Assets | 69.27B | 60.49B | 58.40B | 66.38B | 69.76B |
| Cash, Cash Equivalents and Short-Term Investments | 2.13B | 2.06B | 2.90B | 3.61B | 1.84B |
| Total Debt | 17.58B | 18.80B | 25.17B | 30.30B | 30.25B |
| Total Liabilities | 37.78B | 34.62B | 37.68B | 44.66B | 45.93B |
| Stockholders Equity | 31.08B | 25.52B | 21.26B | 22.12B | 23.59B |
Cash Flow | |||||
| Free Cash Flow | 1.21B | 4.42B | 5.83B | -505.27M | -4.01B |
| Operating Cash Flow | 5.39B | 6.84B | 7.01B | 444.11M | -2.58B |
| Investing Cash Flow | -1.78B | -896.89M | -1.50B | 3.02B | -1.19B |
| Financing Cash Flow | -2.85B | -6.43B | -6.93B | -2.14B | 4.21B |
Strides Pharma Science Ltd Technical Analysis
Positive
983.10
Price Trends
1036.06
Negative
1055.44
Negative
974.10
Positive
Market Momentum
-5.58
Negative
54.59
Neutral
69.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:STAR, the sentiment is Positive. The current price of 983.1 is below the 20-day moving average (MA) of 990.29, below the 50-day MA of 1036.06, and above the 200-day MA of 974.10, indicating a neutral trend. The MACD of -5.58 indicates Negative momentum. The RSI at 54.59 is Neutral, neither overbought nor oversold. The STOCH value of 69.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:STAR.
Strides Pharma Science Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹971.92B | 29.48 | ― | 0.69% | -0.92% | -41.75% | |
69 Neutral | ₹972.39B | 26.30 | ― | 0.26% | 9.09% | 9.61% | |
69 Neutral | ₹4.69T | 38.27 | ― | 0.82% | 11.41% | 16.62% | |
67 Neutral | ₹285.51B | -89.96 | ― | 0.08% | 0.78% | -420.81% | |
61 Neutral | ₹94.44B | 15.39 | ― | 0.39% | 7.28% | 68.82% | |
60 Neutral | ₹1.03T | 91.93 | ― | 0.12% | 22.62% | 114.66% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:STAR
Strides Pharma Science Ltd
1,047.30
154.63
17.32%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,656.30
621.25
60.02%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,161.00
-93.60
-7.46%
IN:LAURUSLABS
Laurus Labs Ltd.
1,863.00
989.39
113.25%
IN:PPLPHARMA
Piramal Pharma Limited
213.65
12.45
6.19%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,933.00
367.70
23.49%
Strides Pharma Science Ltd Corporate Events
Strides Clinches USFDA EIR for Flagship Bengaluru Plant, Bolstering Global Supply Ambitions
Aug 19, 2026
Strides Pharma Science Ltd, a Bengaluru-headquartered global drug maker listed in Mumbai, focuses on complex, hard-to-make formulations for regulated markets and donor-funded programs, with a notable footprint in Africa. Its diversified manufactur...
Strides Pharma Files SEBI Compliance Certificate on Share Dematerialisation
Jul 8, 2026
Strides Pharma Science Limited has submitted to the Indian stock exchanges a compliance certificate under regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026. The certificate, issued by it...
Strides Pharma to Close Trading Window Ahead of Q1 FY27 Results
Jun 24, 2026
Strides Pharma Science has announced that its trading window for dealing in company shares will be closed from July 1, 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and its internal code of conduct. The window will reo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.